CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · IEX Real-Time Price · USD
1.670
-0.060 (-3.47%)
Apr 19, 2024, 4:00 PM EDT - Market closed
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 3.13, with a low estimate of 3.00 and a high estimate of 3.25. The average target predicts an increase of 87.43% from the current stock price of 1.67.
Analyst Consensus: Hold
* Price targets were last updated on Mar 12, 2024.
Analyst Ratings
The average analyst rating for CTMX stock from 2 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Hold Maintains $3.3 → $3.25 | Hold | Maintains | $3.3 → $3.25 | +94.61% | Mar 12, 2024 |
| Wedbush | Wedbush | Hold Reiterates $3 | Hold | Reiterates | $3 | +79.64% | Mar 12, 2024 |
| Wedbush | Wedbush | Hold Maintains $2 → $3 | Hold | Maintains | $2 → $3 | +79.64% | Nov 9, 2023 |
| Wedbush | Wedbush | Hold → Buy Upgrades $2 → $3 | Hold → Buy | Upgrades | $2 → $3 | +79.64% | Nov 8, 2023 |
| BMO Capital | BMO Capital | Hold Maintains $3.15 → $3.19 | Hold | Maintains | $3.15 → $3.19 | +91.02% | Aug 9, 2023 |
Financial Forecast
Revenue This Year
92.36M
from 101.21M
Decreased by -8.75%
Revenue Next Year
79.03M
from 92.36M
Decreased by -14.43%
EPS This Year
-0.19
from -0.01
EPS Next Year
-0.38
from -0.19
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 113.4M | 113.4M | 93.7M | 155.3M | 170.8M |
| Avg | 92.4M | 79.0M | 45.5M | 77.8M | 118.1M |
| Low | 78.4M | 25.5M | n/a | 10.2M | 87.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 12.0% | 22.8% | 18.5% | 241.3% | 119.6% |
| Avg | -8.7% | -14.4% | -42.4% | 71.0% | 51.8% |
| Low | -22.5% | -72.4% | - | -77.5% | 12.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.04 | -0.13 | -0.29 | 0.27 | 0.28 |
| Avg | -0.19 | -0.38 | -0.79 | -0.17 | 0.07 |
| Low | -0.47 | -1.09 | -1.20 | -0.59 | -0.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.